Aradigm
Benefits platform for cell and gene therapies designed to provide sustainable access to life-saving medicines.
- Founded
- 2024
- Headquarters
- Bethesda, MD
- Employees
- 11-50
- Latest Round
- Series A
- Est. Valuation
- ~$90M
Investment Thesis
Cell and gene therapies can cure devastating diseases but cost $1-4M per treatment. Employers and health plans cannot predict or absorb these costs.
Aradigm creates a large-scale risk pool to cover CGT drugs and care, with unspent funds returned. Includes national centers of excellence, concierge support, and end-to-end delivery.
The CGT pipeline is exploding with dozens of therapies at $1-4M each. Without a sustainable financial model, most patients will never access these cures.
Public benefit corporation launched from stealth. Novel risk-pooling model that addresses every stakeholder incentive.
Dr. William Shrank (CEO), physician with leadership at Humana, UPMC, CVS Health, and CMS Innovation Center.